Company NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
3.21 ^USD	-5.59%		-15.75%	-30.22%

Jun. 03	Certain Warrant of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-JUN-2024.	CI
Jun. 03	Certain Common Stock of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-JUN-2024.	CI

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

Managers	Title	Age	Since
Stephen Willard CEO	Chief Executive Officer	63	22-07-11
Jonathan Javitt FOU	Founder	67	17-09-17
Richard Narido DFI	Director of Finance/CFO	46	23-09-12
Carrie M. Carretta CTO	Chief Tech/Sci/R&D Officer	-	22-12-04
Rick Panicucci CTO	Chief Tech/Sci/R&D Officer	63	-
Dennis K. McBride PRN	Corporate Officer/Principal	-	15-09-30

Members of the board	Title	Age	Since
Jonathan Javitt FOU	Founder	67	17-09-17
Stephen Willard CEO	Chief Executive Officer	63	22-07-11
Janet Rehnquist BRD	Director/Board Member	-	Dec. 26
Patrick J. Flynn BRD	Director/Board Member	75	21-05-23
Chaim Hurvitz BRD	Director/Board Member	64	21-05-23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,700,609	7,802,450 ( 72.92 %)	0	72.92 %
Stock B	0	3,000,000	0	0

Name	Equities	%	Valuation
Jonathan Javitt 14.08 %	1,476,833	14.08 %	5 M $
Daniel Javitt 9.413 %	987,291	9.413 %	3 M $
Chaim Hurvitz 2.112 %	221,479	2.112 %	695 444 $
Vanguard Group, Inc. (Subfiler) 1.373 %	144,005	1.373 %	452 176 $
Stephen Willard 1.001 %	105,000	1.001 %	329 700 $
AdvisorShares Investments LLC 0.5862 %	61,479	0.5862 %	193 044 $
Patrick Flynn 0.5629 %	59,034	0.5629 %	185 367 $
Geode Capital Management LLC 0.4004 %	41,995	0.4004 %	131 864 $
BlackRock Institutional Trust Co. NA 0.2772 %	29,071	0.2772 %	91 283 $
Renaissance Technologies LLC 0.1800 %	18,878	0.1800 %	59 277 $

Name	Equities	%	Valuation
G1 Execution Services LLC -	13,436	-	1 962 $
Wolverine Asset Management LLC -	2,157	-	315 $
Tower Research Capital LLC -	15	-	2 $

NRX Pharmaceuticals, Inc.

1201 Orange Street Suite 600

19801, Wilmington

http://www.nrxpharma.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.21 USD

Average target price

31.5 USD

Spread / Average Target

+881.31%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NRX PHARMACEUTICALS, INC.	-30.22%	33.74M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research